Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics. Its lead product candidate, deramiocel (CAP-1002), is in Phase 3 clinical development for Duchenne muscular dystrophy (DMD). The company also maintains a preclinical exosome-based platform (StealthX™) for vaccines and therapeutics.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $3.97 million | $8.88 million |
| Net Loss | $(11.00) million | $(20.79) million |
| Loss Per Share (Basic & Diluted) | $(0.35) | $(0.66) |
| Operating Expenses | $15.56 million | $30.74 million |
| Cash, Cash Equivalents & Marketable Securities | $29.46 million (as of June 30, 2024) | |
| Working Capital | $8.31 million (as of June 30, 2024) | |
| Accumulated Deficit | $(180.16) million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $8.88 million for the six months ended June 30, 2024, compared to $6.90 million in the prior year period. This increase is primarily due to the recognition of revenue from the U.S. Distribution Agreement with Nippon Shinyaku, including a $10.0 million milestone payment received in Q1 2024 upon the completion of the interim futility analysis of the HOPE-3 trial.
- Expense Increases:
- R&D Expenses: Increased 43% year-over-year to $23.61 million (six months), driven by higher costs for the HOPE-3 Phase 3 trial, expanded manufacturing production, and increased headcount.
- G&A Expenses: Increased 12% year-over-year to $7.13 million (six months), primarily due to higher stock-based compensation and depreciation.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from approximately $39.5 million at December 31, 2023, to $29.5 million at June 30, 2024, reflecting operating cash burn.
Guidance, Outlook, and Risks
- Going Concern Warning: The company has disclosed substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations only into the first quarter of 2025. Additional financing will be required to support ongoing operations and clinical trials.
- Clinical Milestones:
- HOPE-3 (DMD): Top-line data for Cohort A is expected in the fourth quarter of 2024. This data is intended to support a Biologics License Application (BLA).
- StealthX™ (Exosomes): The company's vaccine candidate for SARS-CoV-2 has been selected for Project NextGen. NIAID plans to initiate a Phase 1 clinical study in late 2024 or early 2025.
- Financing Activities: During the six months ended June 30, 2024, the company raised approximately $4.3 million in net proceeds through its At-The-Market (ATM) offering. Subsequent to the quarter end, an additional $2.5 million was raised.
- Risks: Key risks include the failure to raise additional capital, potential dilution from equity issuances, delays in clinical trials, and the uncertainty of regulatory approval for deramiocel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $29.5 million cash balance against the projected burn rate to confirm the "first quarter 2025" liquidity estimate.
- HOPE-3 Trial Status: Monitor the timeline for the Q4 2024 top-line data readout for Cohort A, which is critical for the BLA submission.
- Financing Needs: Assess the company's ability to secure additional funding given the "substantial doubt" disclosure and the current market environment.
- Deferred Revenue: Review the $15.4 million in deferred revenue (primarily from Nippon Shinyaku) and the assumptions regarding the recognition timeline.
- Intellectual Property Disputes: Note the resolved claim by Cedars-Sinai Medical Center regarding a 10% share of the $10 million milestone, which was withdrawn after discussions.